Skip to main content

Seattle biotech Alpine Immune Sciences raises $91M for drug development

The company, which went public in 2017, is developing drugs to help patients with autoimmune and inflammatory diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.